Abstract: Polypeptides, antibodies or antigen-binding fragments capable of binding to prostate specific membrane antigen (PSMA) are provided. These polypeptides, antibodies or antigen-binding fragments may be used for diagnostic and/or therapeutic purposes.
Type:
Application
Filed:
April 14, 2009
Publication date:
August 4, 2011
Applicant:
PROSCAN RX PHARMA
Inventors:
Serge Moffett, Dominic Melancon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
Type:
Grant
Filed:
January 28, 2004
Date of Patent:
October 12, 2010
Assignee:
Proscan RX Pharma
Inventors:
Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
Type:
Application
Filed:
April 19, 2005
Publication date:
May 21, 2009
Applicant:
PROSCAN RX PHARMA
Inventors:
Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett